Last updated on May 2018

Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain


Brief description of study

This study is to provide safety information of hemoporfin during the post-marketing period as required by China Food and Drug Administration (CFDA) regulations in order to identify any potential drug related treatment factors in the Chinese population, such as unknown/unexpected adverse reactions, the incidence of adverse reactions under the routine drug uses.

Clinical Study Identifier: NCT03181984

Contact Investigators or Research Sites near you

Start Over

Jining Tao

Shanghai Dermatology Hospital
Shanghai, China
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.